5/8/2013 11:04:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Since the autumn of 2012, the Board of ONCOlog has worked to find buyers for the sale of the entire company or its assets. However, these efforts have not been successful and the ONCOlog Board has therefore not seen any alternative left but to apply for the company to be declared bankrupt. Allenex owns 14.9% of ONCOlog, but has since mid-2011 changed its focus to include the transplantation area only. Allenex has since this strategic shift not financed ONCOlog in any way. Therefore, the ONCOlog bankruptcy will not have any effect on Allenex` financial results. This is due to the fact that the Allenex holding in ONCOlog is already valued at zero and that no other commitments exist.
Allenex AB (STO:ALNX) discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 08, 2013, at 12.45 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.
This information was brought to you by Cision http://news.cision.com
CEO Allenex AB
ph.: +4670-918 00 10
Help employers find you! Check out all the jobs and post your resume.
comments powered by